Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pryma

Showing results (51-60 of 124) with videos related to

Pageof 13
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 23, 2011
Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250Daniel A Pryma, Joseph A O'Donoghue, John L Humm, et al.
Endocrine-Related Cancer|December 6, 2022
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paragangliomaCamilo Jimenez, Bennett B Chin, Richard B Noto, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2025
Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatraceVictor V Onecha, Daniel Suarez-García, Jesús J Bosque, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 2024
The Lancet Oncology Commission: Radiotherapy & Theranostic Services in LMICs: Minding & Mending the GapsJaleelat I Momodu, Claudia Carvajal, Daniel A Pryma, et al.
International Journal of Radiation Oncology, Biology, Physics|November 29, 2020
A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus DocumentJohn M Buatti, Daniel A Pryma, Ana P Kiess, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2019
PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human NeuroblastomaHwan Lee, Aladdin Riad, Paul Martorano, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 25, 2017
PARP-1 Expression Quantified by [<sup>18</sup>F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation TherapySamuel Sander Effron, Mehran Makvandi, Lilie Lin, et al.
Urology|March 5, 2013
A review of contemporary data on surgically resected renal masses--benign or malignant?Anthony T Corcoran, Paul Russo, William T Lowrance, et al.
Plos One|February 14, 2020
The role of resting myocardial blood flow and myocardial blood flow reserve as a predictor of major adverse cardiovascular outcomesMarie A Guerraty, H Shanker Rao, Venkatesh Y Anjan, et al.
Transplantation|June 22, 2022
Where LI-RADS Falls Short: Two Cases of Image-diagnosed HCC, Found to Be NET on ExplantNicholas R Perkons, David C Metz, Evan S Siegelman, et al.
Pageof 13

Showing results (51-60 of 124) with videos related to

Sort By:
Pageof 13
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 23, 2011
Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250Daniel A Pryma, Joseph A O'Donoghue, John L Humm, et al.
Endocrine-Related Cancer|December 6, 2022
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paragangliomaCamilo Jimenez, Bennett B Chin, Richard B Noto, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2025
Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatraceVictor V Onecha, Daniel Suarez-García, Jesús J Bosque, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 2024
The Lancet Oncology Commission: Radiotherapy & Theranostic Services in LMICs: Minding & Mending the GapsJaleelat I Momodu, Claudia Carvajal, Daniel A Pryma, et al.
International Journal of Radiation Oncology, Biology, Physics|November 29, 2020
A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus DocumentJohn M Buatti, Daniel A Pryma, Ana P Kiess, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2019
PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human NeuroblastomaHwan Lee, Aladdin Riad, Paul Martorano, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 25, 2017
PARP-1 Expression Quantified by [<sup>18</sup>F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation TherapySamuel Sander Effron, Mehran Makvandi, Lilie Lin, et al.
Urology|March 5, 2013
A review of contemporary data on surgically resected renal masses--benign or malignant?Anthony T Corcoran, Paul Russo, William T Lowrance, et al.
Plos One|February 14, 2020
The role of resting myocardial blood flow and myocardial blood flow reserve as a predictor of major adverse cardiovascular outcomesMarie A Guerraty, H Shanker Rao, Venkatesh Y Anjan, et al.
Transplantation|June 22, 2022
Where LI-RADS Falls Short: Two Cases of Image-diagnosed HCC, Found to Be NET on ExplantNicholas R Perkons, David C Metz, Evan S Siegelman, et al.
Pageof 13